Literature DB >> 18249119

The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998-2000.

Lawrence Cher1, Mark A Rosenthal, Katharine J Drummond, Michael Dally, Michael Murphy, David Ashley, Vicky Thursfield, Graham G Giles.   

Abstract

Chemotherapy has an increasing role in the management of gliomas. In particular, chemotherapy provides survival and quality of life benefits in the setting of recurrent high-grade gliomas and in patients with newly diagnosed glioblastoma multiforme. We have previously reported details on patterns of care regarding 828 patients diagnosed with a glioma in the state of Victoria for the period 1998-2000. We observed that 250 patients (30%) received chemotherapy at some stage of their illness, including neo-adjuvant, adjuvant and recurrent clinical settings. There was significant variation in the agents used and their scheduling. Chemotherapy was given at any time in only 15% of patients aged over 60 years. Eight percent of patients were enrolled on a chemotherapy clinical trial. As chemotherapy for gliomas becomes entrenched as the standard of care, this survey will provide an insight into changing patterns of care for the future and points to areas of need in management of these tumours.

Entities:  

Mesh:

Year:  2008        PMID: 18249119     DOI: 10.1016/j.jocn.2007.04.001

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004.

Authors:  Luc Bauchet; Hélène Mathieu-Daudé; Pascale Fabbro-Peray; Valérie Rigau; Michel Fabbro; Olivier Chinot; Loreleï Pallusseau; Charlotte Carnin; Karl Lainé; Aline Schlama; Agnes Thiebaut; Maria Cristina Patru; Fabienne Bauchet; Martine Lionnet; Michel Wager; Thierry Faillot; Luc Taillandier; Dominique Figarella-Branger; Laurent Capelle; Hugues Loiseau; Didier Frappaz; Chantal Campello; Christine Kerr; Hugues Duffau; Monique Reme-Saumon; Brigitte Trétarre; Jean-Pierre Daures; Dominique Henin; François Labrousse; Philippe Menei; Jérome Honnorat
Journal:  Neuro Oncol       Date:  2010-04-02       Impact factor: 12.300

Review 2.  MicroRNA as potential biomarkers in Glioblastoma.

Authors:  Zammam Areeb; Stanley S Stylli; Rachel Koldej; David S Ritchie; Tali Siegal; Andrew P Morokoff; Andrew H Kaye; Rodney B Luwor
Journal:  J Neurooncol       Date:  2015-09-21       Impact factor: 4.130

3.  Trends in classification, referral and treatment and the effect on outcome of patients with glioma: a 20 year cohort.

Authors:  S C Erridge; M G Hart; G R Kerr; C Smith; S McNamara; R Grant; A Gregor; I R Whittle
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

4.  Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.

Authors:  C Gzell; H Wheeler; L Guo; M Kastelan; M Back
Journal:  J Neurooncol       Date:  2014-05-15       Impact factor: 4.130

5.  Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.

Authors:  Zammam Areeb; Sarah F Stuart; Alice J West; Juliana Gomez; Hong P T Nguyen; Lucia Paradiso; Ahmad Zulkifli; Jordan Jones; Andrew H Kaye; Andrew P Morokoff; Rodney B Luwor
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.